Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025)

Monopar Therapeutics (MNPR) reported Other Operating Expenses of -$1.0 for Q3 2025, down 100.0% sequentially from $14.5 million in Q3 2017.

Monopar Therapeutics (MNPR) Other Operating Expenses (2017 - 2025) Analysis & Trends

Monopar Therapeutics (MNPR) has 2 years of Other Operating Expenses data on file, last reported at -$1.0 in Q3 2025.

For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to -$1.0; the trailing twelve-month figure through Dec 2025 stood at -$1.0 (changed N/A YoY), and the FY2017 full-year result was $14.5 million, changed N/A from the prior year.
Other Operating Expenses slipped to -$1.0 in Q3 2025, from $14.5 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of -$1.0 in Q3 2025 to a low of -$1.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Monopar Therapeutics	707.36 Mn	645.53 Mn	-

Download Data

Date	Value
Sep 30, 2025	-1.00
Sep 30, 2017	14.50 Mn